Matthew J Cotter
Overview
Explore the profile of Matthew J Cotter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gopal A, Popat R, Mattison R, Menne T, Bloor A, Gaymes T, et al.
Int J Hematol Oncol
. 2021 Nov;
10(3):IJH35.
PMID: 34840720
Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. Patients & Methods: This Phase I, two-cohort, dose-escalation trial ...
2.
Kraus A, Yu-Kite M, Mardekian J, Cotter M, Kim S, Decembrino J, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(1):302-309.
PMID: 34668577
This report examined the benefits and risks of palbociclib plus endocrine therapy (ET) in men with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib...
3.
Brufsky A, Mitra D, Davis K, Nagar S, McRoy L, Cotter M, et al.
Clin Breast Cancer
. 2019 May;
19(5):317-325.e4.
PMID: 31104984
Purpose: To evaluate treatment patterns and clinical outcomes of patients who received palbociclib in combination with letrozole in any line of therapy for treatment of hormone receptor-positive, human epidermal growth...
4.
Stearns V, Brufsky A, Verma S, Cotter M, Lu D, Dequen F, et al.
Clin Breast Cancer
. 2018 Sep;
18(6):e1239-e1245.
PMID: 30172722
Purpose: Palbociclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that was conditionally approved in the United States (February 2015) and Canada (March 2016) with letrozole as initial endocrine-based...
5.
Finkelstein S, Iclozan C, Bui M, Cotter M, Ramakrishnan R, Ahmed J, et al.
Int J Radiat Oncol Biol Phys
. 2011 Mar;
82(2):924-32.
PMID: 21398051
Purpose: The goal of this study was to determine the effect of combination of intratumoral administration of dendritic cells (DC) and fractionated external beam radiation (EBRT) on tumor-specific immune responses...
6.
Corzo C, Condamine T, Lu L, Cotter M, Youn J, Cheng P, et al.
J Exp Med
. 2010 Sep;
207(11):2439-53.
PMID: 20876310
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and...
7.
Nagaraj S, Youn J, Weber H, Iclozan C, Lu L, Cotter M, et al.
Clin Cancer Res
. 2010 Mar;
16(6):1812-23.
PMID: 20215551
Purpose: Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify effective therapeutic means to modulate these...
8.
Zhou J, Cheng P, Youn J, Cotter M, Gabrilovich D
Immunity
. 2009 Jun;
30(6):845-59.
PMID: 19523851
Dendritic cell (DC) differentiation is regulated by stroma via a network of soluble and cell-bound factors. Notch is one of the major elements of this network. Its role in DC...
9.
Zaiss A, Vilaysane A, Cotter M, Clark S, Meijndert H, Colarusso P, et al.
J Immunol
. 2009 May;
182(11):7058-68.
PMID: 19454703
Adenovirus is a nonenveloped dsDNA virus that activates intracellular innate immune pathways. In vivo, adenovirus-immunized mice displayed an enhanced innate immune response and diminished virus-mediated gene delivery following challenge with...
10.
Corzo C, Cotter M, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al.
J Immunol
. 2009 Apr;
182(9):5693-701.
PMID: 19380816
Myeloid-derived suppressor cells (MDSC) are a major component of the immune suppressive network described in cancer and many other pathological conditions. Recent studies have demonstrated that one of the major...